Tonix CCO discloses stock, 40,000-share option
Tonix Pharmaceuticals’ Chief Commercial Officer reported direct ownership of common stock and multiple option grants under the company’s 2020 Stock Incentive Plan.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Filing Summary
Tonix Pharmaceuticals Holding Corp. (TNXP) reported the initial beneficial ownership of its Chief Commercial Officer, Thomas Englese, on a Form 3. He holds 694 shares of common stock directly and several stock options covering 500, 6,500, 12,480 and 40,000 underlying common shares, with exercise prices between $8.05 and $20.18 and expirations from September 9, 2034 to February 24, 2036. Footnotes state these options were granted under Tonix’s Amended and Restated 2020 Stock Incentive Plan and vest over three- or four-year schedules starting on each grant’s first anniversary.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Stock Option F1 | -- | -- | -- |
| holding | Stock Option F2 | -- | -- | -- |
| holding | Stock Option F3 | -- | -- | -- |
| holding | Stock Option F4 | -- | -- | -- |
| holding | Common Stock, $0.001 par value per share | -- | -- | -- |
Footnotes (4)
- F1. The option was granted on September 9, 2024, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
- F2. The option was granted on February 25, 2025, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/3rd on the first anniversary of issuance and 1/36th each month thereafter for 24 months.
- F3. The option was granted on May 13, 2025, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/4th on the first anniversary of issuance and 1/48th each month thereafter for 36 months.
- F4. The option was granted on February 24, 2026, pursuant to the Issuer's Amended and Restated 2020 Stock Incentive Plan, as amended. The option vests 1/4th on the first anniversary of issuance and 1/48th each month thereafter for 36 months.
Key Figures
Key Terms
Form 3 regulatory
Stock Option financial
Amended and Restated 2020 Stock Incentive Plan financial
vesting financial
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Tonix Pharmaceuticals (TNXP) disclose about Thomas Englese’s holdings on this Form 3?
How many Tonix Pharmaceuticals (TNXP) stock options does Thomas Englese hold and at what exercise prices?
When do Thomas Englese’s Tonix (TNXP) stock options expire?
What are the vesting terms of Thomas Englese’s Tonix (TNXP) stock options?
Under what plan were the Tonix (TNXP) options to Thomas Englese granted?
AI-generated analysis. How Rhea-AI works. Not financial advice.